6:14 PM
 | 
Oct 12, 2012
 |  BC Extra  |  Clinical News

Lexicon jumps on Phase II carcinoid syndrome data

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) gained $0.30 (13%) to $2.69 on Friday after reporting data from a Phase II trial of telotristat etiprate to treat refractory carcinoid syndrome. The tryptophan hydroxylase inhibitor...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >